14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha.

Epoxyeicosatrienoic acids (EETs), lipid mediators synthesized from arachidonic acid by cytochrome P-450 epoxygenases, are converted by soluble epoxide hydrolase (SEH) to the corresponding dihydroxyeicosatrienoic acids (DHETs). Originally considered as inactive degradation products of EETs, DHETs have biological activity in some systems. Here we examined the capacity of EETs and DHETs to activate peroxisome proliferator-activated receptor-alpha (PPARalpha). We find that among the EET and DHET regioisomers, 14,15-DHET is the most potent PPARalpha activator in a COS-7 cell expression system. Incubation with 10 microM 14,15-DHET produced a 12-fold increase in PPARalpha-mediated luciferase activity, an increase similar to that produced by the PPARalpha agonist Wy-14643 (20 microM). Although 10 microM 14,15-EET produced a threefold increase in luciferase activity, this was abrogated by the SEH inhibitor dicyclohexylurea. 14-Hexyloxytetradec-5(Z)-enoic acid, a 14,15-EET analog that cannot be converted to a DHET, did not activate PPARalpha. However, PPARalpha was activated by 2-(14,15-epoxyeicosatrienoyl)glycerol, which was hydrolyzed and the released 14,15-EET converted to 14,15-DHET. COS-7 cells incorporated 14,15-[3H]DHET from the medium, and the cells also retained a small amount of the DHET formed during incubation with 14,15-[3H]EET. Binding studies indicated that 14,15-[3H]DHET binds to the ligand binding domain of PPARalpha with a Kd of 1.4 microM. Furthermore, 14,15-DHET increased the expression of carnitine palmitoyltransferase 1A, a PPARalpha-responsive gene, in transfected HepG2 cells. These findings suggest that 14,15-DHET, produced from 14,15-EET by the action of SEH, may function as an endogenous activator of PPARalpha.

[1]  J. Shyy,et al.  Activation of Peroxisome Proliferator-Activated Receptor α by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[2]  A. A. Spector,et al.  Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. , 2005, Microvascular research.

[3]  B. Hammock,et al.  Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. , 2004, American journal of physiology. Heart and circulatory physiology.

[4]  C. Glass,et al.  Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Xiang Fang,et al.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.

[6]  J. Plutzky PPARs as Therapeutic Targets: Reverse Cardiology? , 2003, Science.

[7]  William A. Boisvert,et al.  Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.

[8]  J. Falck,et al.  20-hydroxyeicosatetraenoic acid (20-HETE): structural determinants for renal vasoconstriction. , 2003, Bioorganic & medicinal chemistry.

[9]  A. A. Spector,et al.  Differences in positional esterification of 14,15-epoxyeicosatrienoic acid in phosphatidylcholine of porcine coronary artery endothelial and smooth muscle cells. , 2003, Prostaglandins & other lipid mediators.

[10]  J. Wray,et al.  Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. , 2003, Prostaglandins & other lipid mediators.

[11]  B. Staels,et al.  Peroxisome Proliferator-Activated Receptor &agr; Reduces Cholesterol Esterification in Macrophages , 2003, Circulation research.

[12]  J. Falck,et al.  Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. , 2003, American journal of physiology. Heart and circulatory physiology.

[13]  Eric F. Johnson,et al.  The CYP4A Isoforms Hydroxylate Epoxyeicosatrienoic Acids to Form High Affinity Peroxisome Proliferator-activated Receptor Ligands* , 2002, The Journal of Biological Chemistry.

[14]  J. Liao,et al.  Inhibition of Vascular Smooth Muscle Cell Migration by Cytochrome P450 Epoxygenase-Derived Eicosanoids , 2002, Circulation research.

[15]  J. Falck,et al.  14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels. , 2002, American journal of physiology. Heart and circulatory physiology.

[16]  R. Roman,et al.  P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.

[17]  D. Zeldin Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.

[18]  T. Lu,et al.  Dihydroxyeicosatrienoic acids are potent activators of Ca2+‐activated K+ channels in isolated rat coronary arterial myocytes , 2001, The Journal of physiology.

[19]  R. Busse,et al.  The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells , 2001, Pflügers Archiv.

[20]  D. Thompson,et al.  Pathways of Epoxyeicosatrienoic Acid Metabolism in Endothelial Cells , 2001, The Journal of Biological Chemistry.

[21]  B. Staels,et al.  Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.

[22]  P. Pratt,et al.  Determination of EETs using microbore liquid chromatography with fluorescence detection. , 2000, American journal of physiology. Heart and circulatory physiology.

[23]  J. Rundhaug,et al.  8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[24]  J. Falck,et al.  Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. , 2000, Journal of lipid research.

[25]  X. Fang,et al.  Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. , 1999, Hypertension.

[26]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[27]  R. Busse,et al.  Cytochrome P450 2C is an EDHF synthase in coronary arteries , 1999, Nature.

[28]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[29]  T. Kadowaki,et al.  Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. , 1999, Biochemical and biophysical research communications.

[30]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[31]  R. Razdan,et al.  Total synthesis of 2-Arachidonylglycerol (2-Ara-Gl) , 1999 .

[32]  X. Fang,et al.  14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. , 1998, American journal of physiology. Heart and circulatory physiology.

[33]  N. Weintraub,et al.  Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. , 1998, Circulation research.

[34]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[35]  A. A. Spector,et al.  Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[36]  A. A. Spector,et al.  Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. , 1997, Circulation research.

[37]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[38]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[39]  L. Navar,et al.  Actions of epoxygenase metabolites on the preglomerular vasculature. , 1996, Journal of the American Society of Nephrology : JASN.

[40]  A. A. Spector,et al.  Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. , 1996, Circulation research.

[41]  H. Knapp,et al.  Arachidonic Acid Diols Produced by Cytochrome P-450 Monooxygenases Are Incorporated into Phospholipids of Vascular Endothelial Cells* , 1996, The Journal of Biological Chemistry.

[42]  P. Pratt,et al.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. , 1996, Circulation research.

[43]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[44]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[45]  A. A. Spector,et al.  Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. , 1995, Journal of lipid research.

[46]  J. Mcgiff,et al.  Identification of arachidonate P-450 metabolites in human platelet phospholipids. , 1995, Hypertension.

[47]  M. Noda,et al.  Epoxyeicosatrienoic acid stimulates ADP-ribosylation of a 52 kDa protein in rat liver cytosol. , 1992, The Biochemical journal.

[48]  J. Falck,et al.  Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. , 1991, The American journal of physiology.

[49]  G. FitzGerald,et al.  Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Rosolowsky,et al.  Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. , 1990, Circulation research.

[51]  H. Jacobson,et al.  Cytochrome P450 metabolites of arachidonic acid are potent inhibitors of vasopressin action on rabbit cortical collecting duct. , 1989, The Journal of clinical investigation.

[52]  E. Corey,et al.  Selective epoxidation of eicosa-cis-5,8,11,14-tetraenoic (arachidonic) acid and eicosa-cis-8,11,14-trienoic acid , 1979 .

[53]  C. Djerassi,et al.  Notes - The Direct Conversion of Steroidal 5-3-Alcohols to 5- and 4-3-Ketones , 1956 .